Amanta Healthcare IPO Draws Strong Investor Demand on Day 2; Retail and NII Bids Dominate

New Delhi, September 2, 2025 – The initial public offering (IPO) of Amanta Healthcare Limited witnessed a positive rally on day two of bidding as it reached double-digit oversubscription. As of September 02, 2025, 01:30 PM, the IPO has been 13.60 times oversubscribed. The rally in oversubscription has been led by Non-Institutional Buyers with 22.23 times subscription, closely followed by retail investors with 17.60 times.

Category-wise Subscription Status

Apart from the positive response from Non-Institutional Buyers and retail investors, the IPO has witnessed overall strong investor interest.

As non-institutional buyers oversubscribed their quota by over 22 times, sNIIs led the rally by 32 times and bNIIs at over 17 times, together raising more than ₹420 crore.

Anchor investors also had decent activity as they fully subscribed to their 30 lakh shares, raising ₹37.8 crore.

The QIB (excluding anchor) segment, however, saw weak demand with only 11% subscription. The total application number so far reached 4,22,969.

Key Details About the IPO

Amanta Healthcare IPO will raise ₹126 crore through an entirely fresh issue of 1.00 crore shares. The price for the IPO is to be determined through a book-building process, with the IPO price band set at ₹120.00 to ₹126.00 per share. Beeline Capital Advisors Pvt.Ltd will be the book-running lead manager, and MUFG Intime India Pvt.Ltd will be the registrar of the issue. The IPO opened for subscription on September 1, 2025, and will close on September 3, 2025. Prior to IPO, the company raised ₹37.8 crore from anchor investors, led by Bandhan Small Cap Fund and other institutions.

Amanta Healthcare, headquartered in Ahmedabad, operates in the pharmaceutical and healthcare industry, specialising in sterile intravenous (IV) fluids and injections. Known for its strong manufacturing capabilities, the company supplies to both domestic and international markets. With its upcoming IPO, Amanta Healthcare aims to strengthen its growth trajectory, leveraging its expertise in quality healthcare solutions and expanding its footprint in the pharma sector.

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations